Respiratory Syncytial Virus Infection Therapeutics
1. Rebetol patent expiration
Treatment: Method of using ribavirin in combination with pegylated interferon alpha-2b to treat patients with chronic hepatitis c; Method of using ribavirin in combination with intron a (interferon alpha-2 b rec...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6524570 | SCHERING | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
|
US6524570 (Pediatric) | SCHERING | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
| US6472373 | SCHERING | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep, 2017
(8 years ago) | |
| US6461605 | SCHERING | Continuous low-dose cytokine infusion therapy |
Nov, 2016
(9 years ago) | |
| US6177074 | SCHERING | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
| US6790837 | SCHERING | Ribavirin syrup formulations |
Apr, 2023
(2 years ago) | |
|
US6790837 (Pediatric) | SCHERING | Ribavirin syrup formulations |
Oct, 2023
(2 years ago) | |
|
US6461605 (Pediatric) | SCHERING | Continuous low-dose cytokine infusion therapy |
May, 2017
(8 years ago) | |
|
US6177074 (Pediatric) | SCHERING | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
|
US6172046 (Pediatric) | SCHERING | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar, 2018
(7 years ago) | |
| US6172046 | SCHERING | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep, 2017
(8 years ago) | |
|
US6472373 (Pediatric) | SCHERING | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar, 2018
(7 years ago) | |
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 29 July, 2003
Dosage: SOLUTION
How can I launch a generic of REBETOL before it's drug patent expiration?
More Information on Dosage
REBETOL family patents
2. Rebetol patent expiration
Treatment: Method of tx a pt suspected of having hepatitis c by admin, in combination, a conjugate comprising peg 12000 & interferon alfa-2b in an amt of from 0.5mcg/kg to 2mcg/kg, once weekly, and ribavirin; Me...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6177074 (Pediatric) | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
|
US6524570 (Pediatric) | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
| US6472373 | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep, 2017
(8 years ago) | |
| US6172046 | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep, 2017
(8 years ago) | |
| US6461605 | MERCK SHARP DOHME | Continuous low-dose cytokine infusion therapy |
Nov, 2016
(9 years ago) | |
|
US6172046 (Pediatric) | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar, 2018
(7 years ago) | |
| US6177074 | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
|
US6472373 (Pediatric) | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar, 2018
(7 years ago) | |
| US6524570 | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
|
US6461605 (Pediatric) | MERCK SHARP DOHME | Continuous low-dose cytokine infusion therapy |
May, 2017
(8 years ago) | |
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 03 June, 1998
Dosage: CAPSULE
How can I launch a generic of REBETOL before it's drug patent expiration?
More Information on Dosage
REBETOL family patents